Nathan D Adams

US Patent:

6432938, Aug 13, 2002

Filed:

Jun 9, 1997

Appl. No.:

08/871296

Inventors:

Clive L. Jennings-White - Salt Lake City UT
David L. Berliner - Atherton CA
Nathan W. Adams - West Jordan UT

Assignee:

Pherin Corporation - Mountain View CA

International Classification:

A61K 3156

US Classification:

514177, 514178, 514179, 514182, 552530, 552553, 552555

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e. g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

6437156, Aug 20, 2002

Filed:

Feb 2, 1999

Appl. No.:

09/241594

Inventors:

Clive L. Jennings-White - Salt Lake City UT
David L. Berliner - Atherton CA
Nathan W. Adams - Salt Lake City UT

Assignee:

Pherin Corporation - Mountain View CA

International Classification:

C07J 900

US Classification:

552551, 552552, 552555

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e. g. a 19-nor cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

7407777, Aug 5, 2008

Filed:

Mar 8, 2004

Appl. No.:

10/548153

Inventors:

Wolfram Samlowski - Salt Lake City UT, US
Nathan Bradley Adams - Colchester VT, US
John McGregor - Salt Lake City UT, US

Assignee:

University of Utah Research Foundation - Salk Lake City UT

International Classification:

C12N 5/10
C12N 15/62
C12N 15/63

US Classification:

435 697, 4353201, 435325, 4352523, 536 234

Abstract:

Compounds, genetic constructs, and cancer treatment methods are provided. Expression vectors were designed to express fusion genes including hIL-2 with a Fcε-γ transmembrane anchor derived from a subunit of the FC epsilon receptor. mRNA and the IL-2tm fusion protein was expressed in transfected RD995 tumor cells. Expression of the IL-2tm protein on the tumor cell surface membrane was confirmed by microscopy. RD995 cells transfected with IL-2tm or pCMV2b (empty expression vector) were implanted subcutaneously into C3H/HEN mice. Tumors of mice implanted with 10or 10RD995 cells transfected with IL-2tm grew slower than controls. It is believed that selective expression of cytokines such as IL-2 on the surface of tumors is likely to stimulate tumor-infiltrating lymphocytes that are primed and already recognize tumor antigens, enhancing tumor recognition and killing, potentially avoiding toxicity associated with known cytokine therapies.

US Patent:

20030045514, Mar 6, 2003

Filed:

May 3, 2001

Appl. No.:

09/848247

Inventors:

Louis Monti - Salt Lake City UT, US
David Berliner - Atherton CA, US
Clive Jennings-White - Salt Lake City UT, US
Nathan Adams - West Jordan UT, US

International Classification:

A61K031/57
C07J013/00

US Classification:

514/182000, 552/530000

Abstract:

17-Methyleneandrostan-3-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3-ol is disclosed.

US Patent:

20030220309, Nov 27, 2003

Filed:

Jun 13, 2003

Appl. No.:

10/461788

Inventors:

Louis Monti - Salt Lake City UT, US
David Berliner - Atherton CA, US
Clive Jennings-White - Salt Lake City UT, US
Nathan Adams - West Jordan UT, US

Assignee:

Pherin Pharmaceuticals, Inc.

International Classification:

A61K031/56

US Classification:

514/169000

Abstract:

17-Methylenandrostan-3-ol analogs are useful as corticotropin releasing hormone (CRH) inhibitors, and especially as anti-depressants, when administered to the vomeronasal organ. An improved synthesis of 17-methylenandrost-4-en-3-ol is disclosed.

US Patent:

59943335, Nov 30, 1999

Filed:

Aug 3, 1995

Appl. No.:

8/510957

Inventors:

Clive L. Jennings-White - Salt Lake City UT
David L. Berliner - Atherton CA
Nathan William Adams - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

A61K 3156
C07J 500
C07J 900
C07J 1300

US Classification:

514169

Abstract:

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human vomeropherin, e. g. a pregnane or cholane steroid, or a pharmaceutical composition containing a vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

US Patent:

60574399, May 2, 2000

Filed:

Jul 23, 1996

Appl. No.:

8/686092

Inventors:

Clive L. Jennings-White - Salt Lake City UT
David L. Berliner - Atherton CA
Nathan W. Adams - Salt Lake City UT

Assignee:

Pherin Corporation - Menlo Park CA

International Classification:

C07J 500

US Classification:

540 24

Abstract:

The invention relates to a method of alleviating the symptoms of PMS and anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.

US Patent:

62426192, Jun 5, 2001

Filed:

Aug 11, 1998

Appl. No.:

9/131998

Inventors:

Clive L. Jennings-White - Salt Lake City UT
David L. Berliner - Atherton CA
Nathan W. Adams - West Jordan UT

Assignee:

Pherin Pharmaceuticals, Inc. - Mountain Veiw CA

International Classification:

C07J 500
C07J 700
C07J 1300

US Classification:

552558

Abstract:

Several 19-nor-pregnanes are provided which have the capacity to neurochemically alter the hypothalamic function in an individual through nasal administration. These pharmaceutically active compounds can be administered by themselves or in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers to produce the desired effect.